Amanda Lewis

June 24, 2022

Amanda Lewis joined Cuneo Gilbert & LaDuca, LLP from the Federal Trade Commission, where she worked as an attorney in the Bureau of Competition since 2012. While at the FTC, she served for over two and a half years as a Counsel-Detailee to the Antitrust Subcommittee of the House Judiciary Committee.

Amanda was one of the primary authors of the Digital Markets Investigation Majority Staff Report and worked on the big tech legislation currently being considered by Congress. Prior to the FTC, Amanda was an associate at Cravath, Swaine & Moore and a law clerk for Judge Lawrence McKenna of the Southern District of New York. She received her B.A. from New York University in 2002 and her J.D. from Columbia Law School in 2008.

Andrei Iancu – Congressional Testimony: Hearing on the Patent Eligibility Restoration Act (PERA)

October 13, 2025

On October 8th, 2025, Andrei Iancu testified before the Senate Judiciary Committee, Subcommittee on Intellectual Property during the Hearing on the Patent Eligibility Restoration Act (PERA). Iancu, Partner at Sullivan & Cromwell, former Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO), and

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

September 9, 2025

By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,

If Private Sector R&D Is the Future, IP Policy Must Catch Up

September 8, 2025

By Chris Borges The President’s Budget Request for fiscal year 2026 (FY 2026) includes steep cuts to federal research and development (R&D) funding—a troubling signal for U.S. innovation and economic security. While congressional committees may push back on the most severe reductions, the signs are clear: Federal R&D funding is likely